Advanced in Congenital Hepatic Fibrosis

Dr. Michael K. Porayko

Gastroenterology
Nashville, TN 
Advanced in Congenital Hepatic Fibrosis
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Porayko is a Gastroenterologist in Nashville, Tennessee. Dr. Porayko is rated as an Advanced provider by MediFind in the treatment of Congenital Hepatic Fibrosis. His top areas of expertise are Banti's Syndrome, Hepatitis, Cirrhosis, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gastroenterology
Licenses
Internal Medicine in TN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Nashville, TN 37232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Other, Drug
Study Drug: ARO-AAT
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 2 Randomized, Dose-Titration, Open-Label Study Evaluating the Safety and Efficacy of BIV201 Compared to Standard of Care to Reduce Ascites and Complications in Cirrhotic Patients With Refractory Ascites
A Phase 2 Randomized, Dose-Titration, Open-Label Study Evaluating the Safety and Efficacy of BIV201 Compared to Standard of Care to Reduce Ascites and Complications in Cirrhotic Patients With Refractory Ascites
Enrollment Status: Terminated
Publish Date: May 08, 2024
Intervention Type: Drug
Study Drug: Terlipressin Diacetate
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
Enrollment Status: Terminated
Publish Date: January 09, 2024
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis
Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis
Enrollment Status: Completed
Publish Date: October 31, 2022
Intervention Type: Drug, Other
Study Drugs: Vitamin E, Ropinirole
Study Phase: Phase 4
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
Enrollment Status: Completed
Publish Date: April 06, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

9 Total Publications

Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites.
Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites.
Journal: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
Published: December 10, 2024
Similar Doctors
Advanced in Congenital Hepatic Fibrosis
Dr. Donald Lazas
Gastroenterology
Advanced in Congenital Hepatic Fibrosis
Dr. Donald Lazas
Gastroenterology
5653 Frist Blvd, Suite 530, 
Hermitage, TN 
 (9.9 miles away)
615-885-1093
Languages Spoken:
English
See accepted insurances

Donald Lazas is a Gastroenterologist in Hermitage, Tennessee. Dr. Lazas is rated as an Experienced provider by MediFind in the treatment of Congenital Hepatic Fibrosis. His top areas of expertise are Congenital Hepatic Fibrosis, Familial Adenomatous Polyposis, Esophagitis, Gastric Dysmotility, and Endoscopy.

Advanced in Congenital Hepatic Fibrosis
Dr. Babu Rao
Gastroenterology
Advanced in Congenital Hepatic Fibrosis
Dr. Babu Rao
Gastroenterology

Commonwealth Health Corporation, Inc.

250 Park St, 
Bowling Green, KY 
 (60.7 miles away)
270-781-7178
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Babu Rao is a Gastroenterologist in Bowling Green, Kentucky. Dr. Rao is rated as a Distinguished provider by MediFind in the treatment of Congenital Hepatic Fibrosis. His top areas of expertise are Hiatal Hernia, Congenital Diaphragmatic Hernia, Visceromegaly, Endoscopy, and Gastrostomy.

Experienced in Congenital Hepatic Fibrosis
Dr. Robert W. Herring
Gastroenterology
Experienced in Congenital Hepatic Fibrosis
Dr. Robert W. Herring
Gastroenterology
330 Wallace Rd, Suite103, 
Nashville, TN 
 (7.0 miles away)
615-832-5530
Languages Spoken:
English
See accepted insurances

Robert Herring is a Gastroenterologist in Nashville, Tennessee. Dr. Herring is rated as an Advanced provider by MediFind in the treatment of Congenital Hepatic Fibrosis. His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Hepatitis C, Non-Alcoholic Fatty Liver Disease, and Hepatitis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Porayko's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile